We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Evelo Biosciences Inc
9 own
13 watching
Current Price
$0
$0
(-2.06%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
12.91M
52-Week High
3.29
52-Week Low
0.0243
Average Volume
0.36M
Dividend Yield
--
P/E Ratio
--
Market Capitalization12.91M52-Week High3.2952-Week Low0.0243Average Volume0.36MDividend Yield--P/E Ratio--What does the Evelo Biosciences Inc do?
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Evelo Biosciences Inc make?
News & Events about Evelo Biosciences Inc.
Ticker Report
2 months ago
Evelo Biosciences (NASDAQ:EVLO Get Rating) had its target price lowered by BMO Capital Markets from $10.00 to $5.00 in a research note released on Friday morning, The Fly reports. Several other research firms have also issued reports on EVLO. Jefferies Financial Group lowered shares of Evelo...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (Evelo or the Company) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported ...
Zolmax
5 months ago
Evelo Biosciences, Inc. (NASDAQ:EVLO Get Rating) was the target of unusually large options trading activity on Wednesday. Investors bought 1,885 put options on the company. This is an increase of approximately 1,101% compared to the typical daily volume of 157 put options. Wall Street Analyst Weigh ...
Ticker Report
5 months ago
Evelo Biosciences, Inc. (NASDAQ:EVLO Get Rating) was the target of unusually large options trading activity on Wednesday. Investors bought 1,885 put options on the company. This is an increase of approximately 1,101% compared to the typical daily volume of 157 put options. Wall Street ...
Globe Newswire
5 months ago
CAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced it has entered into a senior secured loan agreement...
Frequently Asked Questions
Frequently Asked Questions
What is Evelo Biosciences Inc share price today?
Can Indians buy Evelo Biosciences Inc shares?
How can I buy Evelo Biosciences Inc shares from India?
Can Fractional shares of Evelo Biosciences Inc be purchased?
What are the documents required to start investing in Evelo Biosciences Inc stocks?
What is today’s traded volume of Evelo Biosciences Inc?
What is today’s market capitalisation of Evelo Biosciences Inc?
What is the 52-Week High and Low Range of Evelo Biosciences Inc?
What percentage is Evelo Biosciences Inc down from its 52-Week High?
What percentage is Evelo Biosciences Inc up from its 52-Week Low?
Current Price
$0
$0
(-2.06%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.